by Plus Therapeutics | May 10, 2024 | Uncategorized
Thank you to everyone who stopped by our booth at the AANS annual meeting to learn more about our ReSPECT Recurrent Glioblastoma and Leptomeningeal Metastases clinical trials! If you missed us and would like more information, you can send us an email at...
by Plus Therapeutics | May 9, 2024 | LM
Plus Therapeutics provided highlights regarding Leptomeningeal Metastases acquisition and topline clinical trial data on the FORESEE Trial on this morning’s investor call. Listen to the Replay: https://edge.media-server.com/mmc/p/nor9kmxs/ Highlights:...
by Plus Therapeutics | May 6, 2024 | GBM
➡️ GLIOBLASTOMA PATIENT WEBINAR ⬅️ Join us as the @MusellaFoundation hosts Dr. Andrew Brenner and Dr. Marc Hedrick in a discussion about the ReSPECT-GBM Phase 2 Clinical Trial for Recurrent Glioblastoma. The webinar will take place May 20 2pm EST with a recording to...
by Plus Therapeutics | May 3, 2024 | Uncategorized
Reminder to come stop by the Plus Therapeutics booth #1057 at the American Association of Neurological Surgeons (AANS) annual conference this weekend in Chicago! Our team will be in the exhibit hall during the entire conference, so come say hello 👋 Home #AANS2024...
by Plus Therapeutics | May 2, 2024 | LM
❗NEW CLINICAL TRIAL INVESTIGATION SITE❗ We are pleased to announce the addition of North Shore University Hospital in New York to our ReSPECT-LM Clinical Trial with Principal Investigator Michael Schulder, M.D.. This site is NOW ENROLLING patients. Michael Schulder,...
Recent Comments